Dec. 25 at 11:33 AM
$SNGX Soligenix is a small biotech company developing a first-in-class, FDA fast-tracked orphan therapy for a rare form of cutaneous lymphoma. Its lead program, HyBryte, is already in Phase 3 with a strong safety profile and a mechanism designed to avoid the long-term risks of UV treatments. While still speculative, the company could offer significant upside if clinical milestones are met
